Status:
COMPLETED
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Male Volunteers
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the excretion pathway of orally administered \[14C\]-BMS-986196 and to assess the safety and tolerability of orally administered BMS-986196.
Eligibility Criteria
Inclusion
- Healthy male participants without clinically significant deviation from normal in medical history, electrocardiogram (ECG), clinical laboratory determinations, and Day -1 physical examination.
- Body mass index of 18.0 to 35.0 kilograms/meter square (kg/m\^2), inclusive, and total body weight ≥ 50 kg
Exclusion
- Any significant acute or chronic medical illness as determined by the investigator.
- A history of clinically significant hepatic or pancreatic disease.
- Current or recent (within 3 months prior to study treatment administration) gastrointestinal disease that could impact upon the absorption, distribution, metabolism, or excretion of study treatment as determined by the investigator.
- Note: Other protocol-defined inclusion/exclusion criteria apply.
Key Trial Info
Start Date :
August 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05981963
Start Date
August 17 2023
End Date
October 22 2023
Last Update
November 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labcorp Clinical Research Unit - Madison
Madison, Wisconsin, United States, 53704-2526